Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bladder cancer
Biotech
Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3
The study fell short of a clean sweep, with Pfizer finding no effect on survival and seeing a higher rate of serious adverse events in the PD-1 arm.
Nick Paul Taylor
Apr 28, 2025 7:25am
Acrivon stops testing Lilly castoff for ovarian, bladder cancer
Mar 26, 2025 7:05am
Pfizer's PD-1 prospect hits goal in phase 3 bladder cancer study
Jan 10, 2025 6:45am
Protara shares spike after bladder cancer data drop
Dec 5, 2024 2:30pm
With ph. 1 data, Aura has an eye on early-stage bladder cancer
Oct 17, 2024 4:05pm
J&J stops phase 3 bladder cancer trial after interim review flop
Oct 8, 2024 4:58am